Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study

Background and purposeLeptomeningeal metastasis (LM) is a rare but detrimental complication in patients with non-small cell lung cancer (NSCLC). Although whole brain radiotherapy (WBRT) is used to eliminating cancer cells or microscopic foci, it is becoming less favorable due to the concerns over ne...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiation oncology (London, England) England), 2020-07, Vol.15 (1), p.1-8, Article 185
Hauptverfasser:	Zhen, Junjie, Wen, Lei, Lai, Mingyao, Zhou, Zhaoming, Shan, Changguo, Li, Shaoqun, Lin, Tao, Wu, Jie, Wang, Wensheng, Xu, Shaoqiang, Liu, Da, Lu, Ming, Zhu, Dan, Chen, Longhua, Cai, Linbo, Zhou, Cheng
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Brain Cancer metastasis Cancer therapies Care and treatment Central nervous system diseases Chemotherapy Cognition Complications and side effects Development and progression Diagnosis EGFR mutation Epidermal growth factor receptors Histology Leptomeningeal metastasis Life Sciences & Biomedicine Lung cancer Magnetic resonance imaging Medical prognosis Meninges Metastases Metastasis Methods Multivariate analysis Mutation Non-small cell lung cancer Non-small cell lung cancer (NSCLC) Non-small cell lung carcinoma Oncology Patient outcomes Patients Prognosis Radiation therapy Radiology, Nuclear Medicine & Medical Imaging Radiotherapy Science & Technology Small cell lung carcinoma Software Survival Survival analysis Toxicity Whole brain radiotherapy (WBRT)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background and purposeLeptomeningeal metastasis (LM) is a rare but detrimental complication in patients with non-small cell lung cancer (NSCLC). Although whole brain radiotherapy (WBRT) is used to eliminating cancer cells or microscopic foci, it is becoming less favorable due to the concerns over neurocognitive toxicity. This study aimed to re-evaluate the role of WBRT in the setting of modern targeted therapy.Materials and methodsFrom December 2014 to March 2019, 80 NSCLC patients with cytologically and/or radiologically proven LM diagnosis were retrospectively analyzed.ResultsThe median OS (mOS) after diagnosis of LM was 8.0 (95%CI: 4.4 to 11.6) months, and the one-year OS was 39.4%. The mOS for EGFR-mutated LM patients was 12.6 (3.0 to 22.2) months versus only 4.1 (2.8 to 5.4) for patients with wild-type EGFR (P
ISSN:	1748-717X 1748-717X
DOI:	10.1186/s13014-020-01627-y